Sort by
Refine Your Search
-
Listed
-
Category
-
Country
-
Field
-
) Application Deadline 19 Mar 2026 - 00:00 (UTC) Country United Kingdom Type of Contract Other Job Status Full-time Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is
-
programme, Deep Molecular Phenotyping of Metastatic Breast Cancer. This ambitious, interdisciplinary project aims to generate an integrated, multi-omic understanding of secondary (metastatic) breast cancer
-
Apr 2026 - 00:00 (UTC) Country United Kingdom Type of Contract Other Job Status Part-time Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related
-
- 00:00 (UTC) Country United Kingdom Type of Contract Other Job Status Full-time Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff
-
(UTC) Country United Kingdom Type of Contract Other Job Status Full-time Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is the Job related to staff position
-
, content management and systems integrations. All projects require some level of design, programming, testing, project management, and customer support. It is essential you have: Proven industrial experience
-
are seeking a collaborative and motivated scientist to work on our newly funded programme developing next-generation, off-the-shelf immunotherapies for childhood cancers. This 12 month project will harness
-
support faculty objectives by working on the development of the faculty marketing plan and managing its implementation, collaborating with a wide range of academic and marketing stakeholders to bring
-
) Application Deadline 30 Mar 2026 - 00:00 (UTC) Country United Kingdom Type of Contract Other Job Status Full-time Is the job funded through the EU Research Framework Programme? Not funded by a EU programme Is
-
postdoctoral scientist to work on our Blood Cancer UK-funded programme developing next-generation, off-the-shelf immunotherapies for acute myeloid leukaemia (AML). This three-year project will harness cytotoxic